Clinical trials: Refractory Pediatric ALL
B-Cell Neoplasm
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and <18 years, ≥6 kg body weight [BW]) with mature…
- Trial name
- DALY PED (NCT06508931)
- Testing
- zamtocabtagene autoleucel (MB-CART2019.1)
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 31 people
- Sponsor
- Miltenyi Biomedicine GmbH
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
This phase I trial studies the best dose and side effects of liposomal cytarabine, daunorubicin, and gemtuzumab ozogamicin in treating pediatric patients with acute myeloid leukemia that has returned after treatment (relapsed) or…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT04915612
- Testing
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
This was a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who were…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- ENSIGN (NCT02228096)
- Testing
- CTL019 T-cells
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer, Leukemia
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00118326
- Testing
- filgrastim, allogeneic bone marrow transplantation
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Wilms' Tumor, Sarcoma
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
This study will evaluate the tolerance and effects of tariquidar, given in combination with one of three anticancer drugs, for treating solid tumors. Tariquidar works by blocking a pump on a cancer cell.
- Conditions
- Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer
- Trial name
- NCT00011414
- Testing
- Tariquidar
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Acute Leukemia, Relapsed Acute Leukemia
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.
- Trial name
- NCT06474663
- Testing
- Cladribine, Cytarabine, Sorafenib
- Sponsor
- M.D. Anderson Cancer Center
Pediatric Cancer, Solid Tumor Cancer
Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid Tumors
Pediatric malignant solid tumors (including neuroblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, and germ cell tumors) account for approximately 60% of childhood malignancies.
- Trial name
- NCT07866534
- Testing
- umbilical cord blood
- Volunteers
- 10 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chronic Graft Versus Host Disease
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
- Trial name
- NCT03790332
- Testing
- Ibrutinib
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 59 people
- Sponsor
- Pharmacyclics LLC.
Neoplasm, Diarrhea
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
The primary purpose of this study is to estimate the maximum tolerated dose of irinotecan with the use of cefpodoxime for pediatric solid tumor patients.
- Trial name
- NCT00143533
- Testing
- Irinotecan, Cefpodoxime
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Leukaemia, Chronic Disease
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
This is a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation.
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia
- Trial name
- NCT00795132
- Testing
- Busulfan, Anti-Thymocyte Globulin, Fludarabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Utah
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Medulloblastoma, Childhood
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting…
- Trial name
- NCT04167618
- Testing
- 177Lu-DTPA-omburtamab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 2 people
- Sponsor
- Y-mAbs Therapeutics
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Neuroblastoma (NB), Ganglioneuroblastoma
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the…
- Trial name
- NB-NK-2026 (NCT07375563)
- Testing
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hepatoblastoma, Pediatric Cancer
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
This study is a single-cohort study. Pediatric patients with advanced, relapsed/refractory hepatoblastoma who have previously failed first-line or higher systemic therapy will receive 2 cycles of treatment with sintilimab…
- Trial name
- NCT07188311
- Testing
- Pucotenlimab ,Lenvatinib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T…
- Trial name
- NCT01748149
- Testing
- Vemurafenib
- Where
- 21 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Epilepsy
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants…
- Trial name
- NCT02914314
- Testing
- perampanel
- Where
- 18 sites in United States, Latvia
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
This phase II trial investigates side effects and how well donor stem cell transplant after chemotherapy works in treating pediatric and adolescent-young adults with high-risk solid tumor that has come back (recurrent) or does…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor
- Trial name
- NCT04530487
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center